Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
NEW YORK, July 2, 2012 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against the Board of Directors of Amylin Pharmaceuticals, Inc. (“Amylin” or the “Company”) (NsadaqGS: AMLN) related to the proposed acquisition of the Company by Bristol-Myers Squibb Company. The transaction is valued at approximately $5.3 billion or $31 per share.
This investigation concerns whether the Board of Directors of Amylin breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the proposed transaction, and whether the Company has disclosed all material information to shareholders about the transaction. Bristol said late Friday it would pay $31 a share to snatch up Amylin. The offer represents a 9.9% premium to Amylin’s closing price Friday of $28.20 a share.
If you are aware of any facts relating to this investigation, or purchased shares of Amylin, you can assist this investigation by contacting either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman, 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC